Stock listing

Lang & Schwarz:A402CB Assembly Biosciences, Inc. Aktie

German listing (Lang & Schwarz) of Assembly Biosciences, Inc. · home listing NASDAQ:ASMB

Follow Assembly Biosciences, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ASMB

$22.19 USD -0.20 (-0.9%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ASMB

Past year -39.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$21.87 – $22.79 USDNov 20, 2026
Volume
480,921 sharesNov 20, 2026
Market cap
$454.4M USDAt the close on Nov 20, 2026 · price × 20.48M shares outstanding
52-week range
$19.20 – $39.65 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.86M USDMedian day 249,358 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Assembly Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ASMB · Home$22.19 USD-0.20 (-0.9%)480,921$22.24$22.79$21.87$22.39Close on Nov 20, 2026
Frankfurt:V7B€19.98 EUR-0.42 (-2.1%)—€19.98€19.98€19.98€20.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ASMB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$22.19-0.20-0.9%$22.24$22.79$21.87480,921
$22.39-0.11-0.5%$22.50$23.50$22.07486,346
$22.50+1.21+5.7%$21.28$22.60$21.15326,387
$21.29+0.17+0.8%$21.12$21.81$21.00514,286
$21.12+0.94+4.7%$19.96$21.21$19.22318,868
$20.18-2.19-9.8%$22.10$22.10$19.84499,583
$22.37+1.02+4.8%$21.11$22.69$21.00203,140
$21.35-0.44-2.0%$21.30$21.69$20.77263,292
$21.79+1.37+6.7%$20.60$21.82$20.03313,333
$20.42+0.42+2.1%$20.00$21.10$20.00249,358
$20.00+0.13+0.7%$20.00$20.06$19.20518,399
$19.87-0.05-0.3%$20.32$20.54$19.64269,004
$19.92+0.41+2.1%$19.71$20.32$19.50170,886
$19.51-0.62-3.1%$20.37$20.77$19.25262,713
$20.13-0.73-3.5%$20.86$21.00$19.98136,867
$20.86+0.29+1.4%$20.75$21.36$20.71198,747
$20.57+0.27+1.3%$20.21$20.66$19.95142,684
$20.30+0.63+3.2%$19.56$20.60$19.56185,733
$19.67-0.17-0.9%$19.97$20.09$19.59152,175
$19.84-0.44-2.2%$20.34$20.34$19.30206,013
$20.28-0.18-0.9%$20.29$20.85$19.98137,800
$20.46-0.73-3.4%$21.42$21.93$20.38234,800
$21.19+1.03+5.1%$20.23$21.48$20.07222,800
$20.16+0.07+0.3%$20.22$20.49$19.95199,200
$20.09-0.48-2.3%$20.63$20.63$19.94167,700
$20.57+0.04+0.2%$20.73$21.04$20.41204,200
$20.53+0.19+0.9%$20.19$20.99$19.98241,300
$20.34-2.43-10.7%$22.64$22.64$20.28305,600
$22.77-0.76-3.2%$23.43$23.83$22.44207,800
$23.53+0.71+3.1%$23.00$23.58$22.72170,500
$22.82-0.13-0.6%$22.78$23.05$22.08288,400
$22.95+0.77+3.5%$21.95$23.13$21.80190,800
$22.18-0.56-2.5%$22.84$22.92$21.80349,200
$22.74+0.20+0.9%$22.68$22.95$22.27241,700
$22.54-0.44-1.9%$23.30$23.48$22.01368,000
$22.98-0.51-2.2%$23.18$23.66$22.75350,800
$23.49+0.010.0%$23.65$23.87$23.23221,100
$23.48-0.13-0.6%$23.70$23.79$23.05229,700
$23.61-0.06-0.3%$23.35$23.86$23.05117,500
$23.67+0.010.0%$23.70$24.25$23.43143,500
$23.66-0.31-1.3%$23.73$24.02$23.15179,000
$23.97-1.48-5.8%$25.42$25.63$23.89275,200
$25.45+0.010.0%$25.69$25.89$25.121,070,100
$25.44+0.47+1.9%$25.40$25.73$24.85211,900
$24.97-0.37-1.5%$25.41$25.78$24.831,413,900
$25.34-0.14-0.5%$26.02$26.30$25.10364,800
$25.48-0.63-2.4%$26.11$26.69$25.13348,800
$26.11-2.85-9.8%$29.00$29.66$25.31588,800
$28.96-0.84-2.8%$30.31$30.48$28.79290,100
$29.80-0.66-2.2%$30.83$31.72$29.68258,900
$30.46-2.41-7.3%$32.56$32.69$30.34348,600
$32.87-2.41-6.8%$35.64$35.93$32.73724,800
$35.28-1.32-3.6%$36.16$36.68$35.15227,700
$36.60+0.47+1.3%$35.68$36.77$35.49156,500
$36.13-0.59-1.6%$36.80$36.80$35.54225,000
$36.72+1.54+4.4%$35.48$37.01$34.86267,500
$35.18+1.55+4.6%$34.12$35.33$33.43301,100
$33.63-0.44-1.3%$33.80$34.30$32.92236,000
$34.07-0.73-2.1%$34.58$34.58$33.29250,000
$34.80-0.62-1.8%$35.32$35.90$34.75192,100
$35.42+0.09+0.3%$35.38$36.13$35.00171,500
$35.33+0.05+0.1%$36.00$37.00$35.19553,800
$35.28+0.90+2.6%$34.38$36.12$33.75383,900
$34.38+0.85+2.5%$33.86$35.62$33.86341,500
$33.53-0.31-0.9%$33.54$34.00$32.90215,000

Splits

2 splits since 2014 · NASDAQ:ASMB · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-5Consolidation
Ticker
Lang & Schwarz:A402CB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Assembly Biosciences, Inc. news

Assembly Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 134 in all · newest Nov 12, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest Nov 5, 2020
Decks
16 decks · latest September 2026

Where Assembly Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ASMB · Home listingNASDAQUnited StatesUSD
Tradegate:V7BTradegateGermanyEUR
LS Exchange:A402CBLS ExchangeGermanyEUR
gettex:V7BgettexGermanyEUR
Lang & Schwarz:A402CB · This pageLang & SchwarzGermanyEUR
BOATS:ASMBBOATSUnited StatesUSD
Frankfurt:V7BFrankfurtGermanyEUR
Dusseldorf:V7BDusseldorfGermanyEUR
Hamburg:V7BHamburgGermanyEUR
Munich:V7BMunichGermanyEUR
Stuttgart:V7BStuttgartGermanyEUR

Valuation

EV/sales 2.1× against a median of 21.2×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$142.3M USD
P/E
Loss
EV/sales
2.1×
EV/EBITDA
Negative EBITDA
Price/book
1.5×
Gross margin
99.9%
Operating margin
−31.8%
Net margin
−16.6%
Debt to equity
0.0×
Beta vs S&P 500
1.00

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
G2GBIO, Inc. · KRX:456160US$449.3MUS$289.1Mn/a176×n/a4.3×−793.7%0.0×n/a
DiaMedica Therapeutics Inc. · NASDAQ:DMACUS$445.1MUS$410.4Mn/an/an/a15.5×n/a0.0×1.67
CytomX Therapeutics, Inc. · NASDAQ:CTMXUS$442.5MUS$98.96Mn/a7.0×n/a1.6×−609.0%0.0×1.21
Hansa Biopharma AB · OMXSTO:HNSAUS$441.3MUS$488.5Mn/a26.3×n/an/a−406.5%n/an/a
Capricor Therapeutics, Inc. · NASDAQ:CAPRUS$441.3MUS$335.9Mn/an/an/a2.1×n/a0.4×0.94
Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373US$439.3MUS$408.1Mn/a16.2×n/a19.4×−57.0%0.9×n/a
Median of the othersUS$447.2MUS$312.5M21.2×2.4×−507.7%0.0×1.19

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
51.20 USD · Analysts' mean
EPS, year to Dec 2026
-0.12 · 4 analysts
Revenue, year to Dec 2026
63.43M · 5 analysts

Team and board

Officers

OfficerRole
Jason OkazakiChief Executive Officer & President, Director
Shannon RyanSVP, Investor Relations, Corporate Affairs and Alliance Management

Board

DirectorRole
Anthony AltigChairman of the Board, Non-Executive
Gina ConsylmanDirector
Jason OkazakiChief Executive Officer & President, Director
John McHutchisonDirector
Lisa Johnson-PrattDirector
Michael HoughtonDirector
Rob CookDirector
Sue MahonyDirector
Tomas CihlarDirector

Events

Calls

CallWhenStatus
Assembly Biosciences (NASDAQ:ASMB) Q3 2020 Earnings CallThu, Nov 05, 2020 · 5:00 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+4.7%
Q2 2026Aug 13, 2026 · After close+10.0%
Q1 2026May 7, 2026 · After close−3.9%
Q3 2025Nov 10, 2025 · After close+3.3%
Q2 2025Aug 6, 2025 · After close+9.2%
Q1 2025May 8, 2025 · After close+5.0%
Q4 2024Mar 26, 2025 · Before open−5.3%
Q3 2024Nov 7, 2024 · After close−4.1%
Q2 2024Aug 8, 2024 · After close−2.8%
Q1 2024May 8, 2024 · After close+1.3%
All 20 quarters
QuarterResultsShare move
Q4 2023Jan 31, 2024 · After close+0.7%
Q3 2023Nov 8, 2023 · After close−12.5%
Q2 2023Aug 9, 2023 · After close+0.9%
Q1 2023May 4, 2023 · After close−1.0%
Q4 2022Mar 22, 2023 · After close−8.6%
Q3 2022Nov 8, 2022 · After close−4.4%
Q2 2022Aug 9, 2022 · After close+0.5%
Q1 2022May 12, 2022 · After close+6.2%
Q4 2021Mar 10, 2022 · After close−1.3%
Quarter to Sep 30, 2021Nov 4, 2021 · After close−1.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck37 slidesSeptember 2026
Technical Presentation (October 2025)Technical15 slidesOctober 2025
Technical Presentation (August 2022)Technical43 slidesAug 31, 2022
Technical Presentation (July 2022)Technical55 slidesJul 26, 2022
AASLD 2019 ReviewConference21 slidesNov 12, 2019
Investor Day (June 2018)Investor day66 slidesJun 20, 2018
Investor Presentation (September 2017)Investor deck37 slidesSep 26, 2017
Technical Presentation (September 2017)Technical31 slidesSep 25, 2017
Investor Presentation (September 2017)Investor deck29 slidesSep 7, 2017
Investor Presentation (January 2017)Investor deck25 slidesJan 9, 2017
All 16 decks
DeckKindSlidesDate
Investor Presentation (November 2016)Investor deck23 slidesNov 9, 2016
RBC Capital Markets 2016 Healthcare ConferenceConference22 slidesFeb 24, 2016
Investor Presentation (January 2016)Investor deck22 slidesJan 12, 2016
Investor Presentation (January 2016)Investor deck22 slidesJanuary 2016
Investor Presentation (February 2015)Investor deck54 slidesFeb 24, 2015
Investor Presentation (August 2014)Investor deck21 slidesAug 13, 2014

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants with accompanying Class A and Class B warrants
Announced: US$19.6 a share · Warrants at US$21.6 for 60 months · Guggenheim Securities +1
Dealers: Guggenheim Securities (lead), Mizuho (co-lead)
Buyers: Commodore Capital; Blackstone Multi-Asset Investing; Farallon Capital Management, L.L.C.; Janus Henderson Investors; RA Capital Management
Use of proceeds: General corporate purposes
Aug 8, 2025
Private placement of common stock with accompanying Class A and Class B warrants
Announced: private placement
Buyers: Gilead Sciences, Inc. (2,295,920 shares of common stock and accompanying Class A and Class B warrants to purchase up to 2,295,920 shares)
Use of proceeds: General corporate purposes
Aug 8, 2025
Strategic investment of common stock
Closed: US$20.1M raised
Buyers: Gilead (approximately $20.1 million equity investment)
Use of proceeds: To advance clinical development programs
Mar 20, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as VENTRUS BIOSCIENCES INC. Priced at US$6.00 a share on Dec 16, 2010.

Price
US$6.00 a share
Shares offered
2,900,000 shares of common stock
Offering size
US$17.4 million
Underwriters' option
Up to 435,000 more shares
Underwriters
Rodman & Renshaw, LLC, National Securities Corporation · In the order on the cover
Shares delivered
On or about Dec 22, 2010

Steps

StepWhen
Filed publiclyJul 20, 2010
Amended 5 timesNewest Dec 9, 2010
Shares registered with an exchangeDec 10, 2010
Declared effective by the SECDec 15, 2010
Final prospectus, with the priceDec 17, 2010

Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2010

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue72.3M28.5M7.16M06.25M79.1M16.0M14.8M9.02M0
Cost of revenue129.0K55.9M48.9M498.0K466.0K101.3M85.8M72.7M44.2M80.3K
Gross profit72.2M-27.4M-41.7M-498.0K6.25M-22.2M16.0M-57.9M-35.2M-80.3K
Research and development64.8M55.9M48.9M70.0M68.5M106.8M85.8M72.7M44.2M33.1M
Selling, general and administrative19.6M18.0M22.9M24.1M28.8M36.9M32.9M34.8M17.0M12.2M
Operating income-12.1M-45.4M-64.6M-94.1M-132.7M-64.8M-102.7M-92.7M-52.2M-45.3M
Depreciation and amortization129.0K129.0K450.0K498.0K466.0K691.0K494.0K643.0K219.0K80.0K
EBITDA-12.0M-45.3M-64.2M-93.6M-132.2M-64.1M-102.2M-92.1M-52.0M-45.2M
Interest expense498.0K82.5M2.62M4.80M000
Income before tax-6.12M-39.8M-61.2M-93.1M-132.4M-62.2M-98.4M-89.7M-51.9M-44.9M
Income tax0330.0K33.0K0-2.53M0-774.0K1.10M-9.05M-618.0K
Net income-6.12M-40.2M-61.2M-93.1M-129.9M-62.2M-97.6M-90.8M-42.8M-44.3M
Earnings per share, basic-0.55-6.69-13.38-23.08-3.00-1.75-3.72-3.98-2.41-2.57
Earnings per share, diluted-0.55-6.69-13.38-23.08-3.00-1.75-3.72-3.98-2.41-2.57

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents58.5M38.3M19.8M52.4M45.6M59.4M46.7M41.5M82.0M28.6M
Short-term investments189.7M73.7M110.4M39.2M101.0M157.0M227.3M176.6M37.9M24.4M
Receivables974.0K043.0K944.0K336.0K1.23M3.37M2.43M2.27M0
Inventory-3.20M1100110
Current assets254.5M115.5M133.8M97.0M154.2M224.5M282.8M222.5M123.1M53.6M
Property, plant and equipment221.0K284.0K385.0K743.0K1.14M1.60M1.83M557.0K860.0K214.7K
Goodwill012.6M12.6M12.6M12.6M12.6M
Total assets257.6M119.2M136.8M101.8M191.1M283.3M339.9M268.0M169.3M98.1M
Accounts payable1.17M585.0K461.0K2.49M2.66M4.60M1.73M3.69M2.12M2.37M
Current liabilities48.8M47.8M39.2M16.3M16.1M24.4M24.4M18.5M13.5M7.12M
Long-term debt00
Total debt2.63M3.09M2.34M3.46M6.48M10.1M12.3M
Total liabilities50.8M85.8M95.7M19.1M22.1M42.7M66.7M57.4M56.2M18.2M
Shareholders' equity206.8M33.4M41.1M82.7M168.9M240.6M273.2M210.7M113.1M79.9M
Shares outstanding15.9M7.46M5.48M4.07M48.1M34.0M32.6M25.5M20.1M17.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-41.1M-51.1M22.7M-84.5M-93.4M-63.0M-84.1M-65.0M1.86M-34.9M
Capital spending-66.0K-28.0K-255.0K-102.0K-3.10M-470.0K-1.55M-340.0K-865.0K-147.0K
Free cash flow-41.2M-51.1M22.5M-84.6M-96.5M-63.4M-85.6M-65.3M995.0K-35.0M
Cash from investing-113.5M40.2M-69.1M90.6M26.5M68.1M-50.3M-135.4M-15.6M36.2M
Cash from financing174.7M29.4M13.8M614.0K53.1M7.60M139.6M159.8M67.2M153.0K
Dividends paid00
Share buybacks614.0K7.60M139.6M159.8M67.2M152.6K
Change in cash20.1M18.5M-32.6M6.79M-13.8M12.7M5.26M-40.6M53.5M1.47M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
S-8 · Registration statement for employee plansAug 20, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K/A · Current report, amendedAug 14, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026Acquisition or disposalSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 4, 2026Big-stake noticeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
8-K · Current reportJun 5, 2026Management or board changeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 27, 2026Big-stake noticeSEC
8-K · Current reportMay 26, 2026Material contractSEC
424B5 · ProspectusMay 22, 2026Offer documentSEC
424B5 · ProspectusMay 22, 2026Offer documentSEC
8-K · Current reportMay 22, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 11, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
8-K · Current reportMar 30, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveMar 30, 2026Other filingsSEC
CORRESP · Letter to the SECMar 25, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 24, 2026Other filingsSEC
S-3 · Registration statementMar 19, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 19, 2026Offer documentSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 19, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
8-K · Current reportDec 8, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 8, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveNov 24, 2025Other filingsSEC
424B3 · ProspectusNov 21, 2025Offer documentSEC
CORRESP · Letter to the SECNov 19, 2025Other filingsSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
S-3 · Registration statementOct 14, 2025Offer documentSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 18, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 18, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
8-K · Current reportAug 11, 2025Material contractSEC
424B5 · ProspectusAug 11, 2025Offer documentSEC
424B5 · ProspectusAug 11, 2025Offer documentSEC
8-K · Current reportAug 8, 2025Current reportSEC
S-3MEFAug 7, 2025Other filingsSEC
S-8 · Registration statement for employee plansAug 6, 2025Offer documentSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
8-K · Current reportJun 25, 2025Current reportSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Management or board changeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
4 · Change in ownershipApr 15, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 2, 2025Other filingsSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
CORRESP · Letter to the SECMar 28, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 26, 2025Other filingsSEC
S-3 · Registration statementMar 20, 2025Offer documentSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
8-K · Current reportFeb 20, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportJan 3, 2025Material contractSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
8-K · Current reportDec 26, 2024Current reportSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 23, 2024Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 23, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 23, 2024Big-stake noticeSEC
8-K · Current reportDec 19, 2024Material contractSEC
8-K · Current reportDec 13, 2024Current reportSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
4 · Change in ownershipNov 19, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 7, 2024Material contractSEC
424B5 · ProspectusNov 7, 2024Offer documentSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipOct 9, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
8-K · Current reportSep 23, 2024Current reportSEC
S-8 · Registration statement for employee plansAug 8, 2024Offer documentSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipJul 8, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 24, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJun 20, 2024Big-stake noticeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 18, 2024Material contractSEC
424B5 · ProspectusJun 18, 2024Offer documentSEC
8-K · Current reportJun 3, 2024Management or board changeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
DEFA14A · Additional proxy materialApr 17, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 17, 2024Annual reportSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
3 · Initial statement of ownershipMar 15, 2024Insider tradeSEC
8-K · Current reportMar 15, 2024Management or board changeSEC
8-K · Current reportFeb 13, 2024Current reportSEC
8-K · Current reportFeb 2, 2024Meeting outcomeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
8-K · Current reportJan 17, 2024Current reportSEC
DEFA14A · Additional proxy materialDec 21, 2023Meeting noticeSEC
DEF 14A · Proxy statementDec 21, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 11, 2023Meeting noticeSEC
3 · Initial statement of ownershipDec 11, 2023Insider tradeSEC
8-K · Current reportDec 7, 2023Management or board changeSEC
SC 13D/A · Big-stake notice, amendedNov 22, 2023Big-stake noticeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 13, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2023Insider tradeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023ResultsSEC
SC 13D/A · Big-stake notice, amendedNov 3, 2023Big-stake noticeSEC
SC 13D · Big-stake noticeOct 31, 2023Big-stake noticeSEC
3 · Initial statement of ownershipOct 31, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 25, 2023Insider tradeSEC
SC 13D · Big-stake noticeOct 25, 2023Big-stake noticeSEC
8-K · Current reportOct 17, 2023Material contractSEC
4 · Change in ownershipOct 4, 2023Insider tradeSEC
4 · Change in ownershipOct 4, 2023Insider tradeSEC
4 · Change in ownershipOct 4, 2023Insider tradeSEC
144 · Notice of proposed saleOct 3, 2023Other filingsSEC
144 · Notice of proposed saleOct 3, 2023Other filingsSEC
8-K · Current reportSep 29, 2023Current reportSEC
3 · Initial statement of ownershipSep 18, 2023Insider tradeSEC
S-8 · Registration statement for employee plansAug 9, 2023Offer documentSEC

This page holds 200 of 904 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Assembly Biosciences, Inc.’s releases · as of Nov 6, 2026

Common shares
20,477,244
Fully diluted
20,477,244

Fully diluted

LineSharesAs of
Common shares20,477,244Nov 6, 2026

Share count over time

CountShares
Nov 6, 202620,477,244
Sep 30, 202620,368,351

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Gilead Sciences, Inc.4.98M24.3%US$117MNo changeNov 5, 2026
Farallon Capital Management, L.L.C.1.6M7.8%US$37.7MNo changeNov 16, 2026
Paradigm Biocapital Advisors LP1.55M7.6%US$36.5MNo changeNov 16, 2026
BlackRock1.49M7.3%US$35M+721KNov 13, 2026
Ra Capital Management, L.P.1.02M5.0%US$24MNo changeNov 16, 2026
Vanguard829K4.0%US$19.5M+100KNov 13, 2026
Parkman Healthcare Partners LLC796K3.9%US$18.7M+75,075Nov 16, 2026
State Street560K2.7%US$13.1M+388KNov 12, 2026
Millennium490K2.4%US$11.5M+191KNov 16, 2026
Commodore Capital LP462K2.3%US$10.9M−953KNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Seven Fleet Capital Management LP417K2.0%US$9.81M−15,706Nov 16, 2026
Citadel380K1.9%US$8.92M+284KNov 16, 2026
Point72 Asset Management, L.P.363K1.8%US$8.52M−97,865Nov 16, 2026
Geode Capital361K1.8%US$8.48M+80,728Nov 6, 2026
Ameriprise288K1.4%US$6.77M+58,397Nov 16, 2026
Hrt Financial LP231K1.1%US$5.42MNewNov 13, 2026
Schonfeld Strategic Advisors LLC228K1.1%US$5.36M−14,151Nov 16, 2026
Dv Equities, LLC226K1.1%US$5.32MNo changeNov 16, 2026
Squadron Capital Management LLC225K1.1%US$5.29M+65,000Nov 16, 2026
Goldman Sachs192K0.94%US$4.5M+53,914Nov 16, 2026
B Group, Inc.176K0.86%US$4.13MNo changeNov 16, 2026
Janus Henderson164K0.80%US$3.85MFirst reportNov 16, 2026
Woodline Partners LP151K0.74%US$3.54MNo changeNov 16, 2026
Northern Trust142K0.69%US$3.34M+19,270Nov 16, 2026
Driehaus Capital Management LLC128K0.63%US$3.01M−21,693Nov 16, 2026
Qube Research & Technologies Ltd114K0.56%US$2.69M+62,934Nov 13, 2026
Franklin Templeton113K0.55%US$2.25MNo changeNov 12, 2026
Renaissance Technologies112K0.55%US$2.63M+72,576Nov 12, 2026
HighVista Strategies LLC93,2240.46%US$2.19M+19,819Nov 13, 2026
Nuveen85,9060.42%US$2.02M+69,031Nov 10, 2026
Squarepoint Ops LLC73,7320.36%US$1.73M+39,518Nov 9, 2026
Morgan Stanley69,1110.34%US$1.62M+23,892Nov 13, 2026
Los Angeles Capital Management LLC60,3420.29%US$1.42MNewNov 12, 2026
Trexquant Investment LP57,1470.28%US$1.34M+11,486Nov 16, 2026
Monimus Capital Management, LP47,5800.23%US$1.12MNo changeNov 16, 2026
Jump Financial, LLC45,8980.22%US$1.08MNewNov 13, 2026
Schwab39,2020.19%US$921K+10,074Nov 16, 2026
Arrowstreet Capital, Limited Partnership38,8570.19%US$913KNewNov 13, 2026
Gsa Capital Partners LLP38,2860.19%US$899K−4,645Nov 16, 2026
UBS35,9090.18%US$844K−5,897Nov 16, 2026
BNP Paribas34,9950.17%US$822K+10,792Nov 12, 2026
Man Group plc34,7130.17%US$815KNewNov 16, 2026
Wellington34,6850.17%US$815KNewNov 16, 2026
BNY32,9720.16%US$775K+8,957Nov 5, 2026
Connor, Clark & Lunn Investment Management Ltd.32,6520.16%US$767K+8,887Nov 10, 2026
XTX Topco Ltd30,7770.15%US$723K−12,141Nov 16, 2026
Engineers Gate Manager LP30,6500.15%US$720K+12,884Nov 16, 2026
Fidelity28,5600.14%US$671K+28,382Nov 10, 2026
HSBC28,4050.14%US$28,689+27,783Nov 16, 2026
Sun Life28,1260.14%US$661KNewNov 12, 2026

This page holds 50 of 100 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund413K2.0%US$11.4M+65,400Jun 30, 2026
iShares Russell 2000 ETF245K1.2%US$6.73MNewJun 30, 2026
Vanguard Extended Market Index Fund133K0.65%US$3.66M+3,257Jun 30, 2026
Fidelity Small Cap Index Fund107K0.52%US$2.7MNewJul 31, 2026
iShares Russell 2000 Value ETF89,2710.44%US$2.45MNewJun 30, 2026
Fidelity Extended Market Index Fund58,3960.29%US$1.62M−693May 31, 2026
Franklin Biotechnology Discovery Fund40,9820.20%US$1.03MNewJul 31, 2026
iShares Micro-Cap ETF33,1350.16%US$911K+9,942Jun 30, 2026
Schwab Small-Cap Index Fund23,7810.12%US$597KNewJul 31, 2026
Fidelity Total Market Index Fund21,2520.10%US$588KNo changeMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Small Cap Value Fund20,7280.10%US$570KNewJun 30, 2026
Master Small Cap Index Series18,4250.09%US$506KNewJun 30, 2026
Fidelity Series Total Market Index Fund16,9170.08%US$468KNo changeMay 31, 2026
Fidelity Small Cap Value Index Fund13,7500.07%US$378KNewJun 30, 2026
Virtus Biotech Clinical Trials Etf13,5370.07%US$340K+5,892Jul 31, 2026
Nuveen Small Cap Blend Index Fund13,2060.06%US$332KNewJul 31, 2026
EQ/2000 Managed Volatility Portfolio10,5750.05%US$291KNewJun 30, 2026
Fidelity Nasdaq Composite Index Fund9,7320.05%US$269KNo changeMay 31, 2026
Avantis U.S. Small Cap Equity ETF9,6500.05%US$267K+3,554May 31, 2026
LVIP State Street Small-Cap Index Fund7,3000.04%US$201KNewJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF6,7160.03%US$169K+2,690Jul 31, 2026
Schwab Total Stock Market Index Fund6,7040.03%US$168KNo changeJul 31, 2026
Vanguard Balanced Index Fund6,3510.03%US$175KNo changeJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund6,0730.03%US$167KNo changeJun 30, 2026
Fidelity ZERO Total Market Index Fund5,7730.03%US$145KNo changeJul 31, 2026
Small Cap Index Fund5,0760.02%US$139KNewJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund4,8100.02%US$132K+1,329Jun 30, 2026
Small Cap Core Fund4,8080.02%US$132K−158Jun 30, 2026
Global X Russell 2000 ETF4,7070.02%US$118KNewJul 31, 2026
ATM Small Cap Managed Volatility Portfolio4,2010.02%US$115KNewJun 30, 2026
Fidelity ZERO Extended Market Index Fund4,0190.02%US$101K+117Jul 31, 2026
Diversified Equity Alpha Master Portfolio3,5470.02%US$97,472NewJun 30, 2026
MetLife Russell 2000 Index Portfolio3,3370.02%US$91,701NewJun 30, 2026
Small-Cap Index Portfolio2,7930.01%US$76,752NewJun 30, 2026
Small Cap Index Trust2,2370.01%US$61,473NewJun 30, 2026
1290 VT Micro Cap Portfolio2,2300.01%US$61,280+565Jun 30, 2026
NVIT Small Cap Index Fund2,1640.01%US$59,467NewJun 30, 2026
EQ/AB Small Cap Growth Portfolio2,020<0.01%US$55,510NewJun 30, 2026
EQ/Small Company Index Portfolio2,020<0.01%US$55,510NewJun 30, 2026
Fidelity Flex Small Cap Index Fund1,791<0.01%US$44,972+98Jul 31, 2026
iShares Russell Small/Mid-Cap Index Fund1,665<0.01%US$41,808NewJul 31, 2026
DWS Small Cap Index VIP1,547<0.01%US$42,512NewJun 30, 2026
1290 VT Small Cap Value Portfolio1,512<0.01%US$41,550NewJun 30, 2026
T. Rowe Price Small-Cap Index Fund1,504<0.01%US$41,330NewJun 30, 2026
Victory Extended Market Index Fund1,441<0.01%US$36,184+241Jul 31, 2026
BlackRock Small Cap Index V.I. Fund1,322<0.01%US$36,329NewJun 30, 2026
Voya RussellTM Small Cap Index Portfolio1,176<0.01%US$32,316NewJun 30, 2026
Avantis U.S. Small Cap Equity Fund1,166<0.01%US$32,252No changeMay 31, 2026
SA Small Cap Index Portfolio1,154<0.01%US$28,977NewJul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio1,100<0.01%US$30,228NewJun 30, 2026

This page holds 50 of 73 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Okazaki Jason A
Director, Officer: CEO and President
Sale6,133USD 19.61US$120KNov 2, 2026
Okazaki Jason A
Director, Officer: CEO and President
Sale69USD 20.35US$1,404Nov 2, 2026
Gaggar Anuj
Officer: Chief Medical Officer
Sale2,564USD 19.61US$50,274Nov 2, 2026
Gaggar Anuj
Officer: Chief Medical Officer
Sale29USD 20.35US$590Nov 2, 2026
White Nicole S
Officer: Chief Manufacturing Officer
Sale2,564USD 19.61US$50,274Nov 2, 2026
White Nicole S
Officer: Chief Manufacturing Officer
Sale29USD 20.35US$590Nov 2, 2026
Bjorkquist Jeanette M
Officer: PFO and PAO
Sale718USD 19.61US$14,078Nov 2, 2026
Bjorkquist Jeanette M
Officer: PFO and PAO
Sale9USD 20.35US$183Nov 2, 2026
Bjorkquist Jeanette M
Officer: PFO and PAO
Sale29USD 23.25US$674Jun 17, 2026

Big stakes

HolderStakeSharesDate
Armistice Capital, LLC9.99%290KJun 30, 2025
Commodore Capital LP9.90%1.62MAug 8, 2025
Ra Capital Management, L.P.9.50%1.53MAug 11, 2025
Farallon Capital Management, L.L.C.8.10%1.6MJun 30, 2026
Paradigm Biocapital Advisors LP7.80%1.55MJun 30, 2026
Janus Henderson Group PLC3.30%674KSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
William R Ringo
Other companies: Sensei Biotherapeutics, Inc. (Director · Mar 8, 2022 – May 21, 2025 · Past); Five Prime Therapeutics Inc (Director · Oct 1, 2014 – Apr 5, 2021 · Past); Immune Design Corp (Director · Jul 23, 2014 – Apr 2, 2019 · Past); Onyx Pharmaceuticals Inc (Director · Feb 3, 2011 – Oct 1, 2013 · Past); Sangamo Therapeutics, Inc. (Director · Apr 16, 2010 – Sep 20, 2017 · Past); Pfizer, Inc. (Senior Vice President · Apr 1, 2008 – Mar 31, 2010 · Past); Allos Therapeutics Inc (Director · Jan 5, 2007 – Jun 19, 2007 · Past); Inspire Pharmaceuticals Inc (Director · Jun 13, 2006 – Jun 8, 2007 · Past); Abgenix Inc (CEO and President, Director · Apr 1, 2006 – Apr 1, 2006 · Past); InterMune Inc (Director · Feb 23, 2006 – May 15, 2007 · Past)
Director · Since at least Jul 10, 2014
Graham Cooper
Other companies: Beam Therapeutics Inc. (Director · Since at least Feb 5, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Jan 27, 2022 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Jun 4, 2015 · Past); Receptos Inc (Chief Financial Officer · May 8, 2013 – Aug 27, 2015 · Past); Geron Corporation (EVP, Bus Dev & CFO · Jan 5, 2012 – May 17, 2012 · Past); Orexigen Therapeutics Inc (CFO and Treasurer · Apr 25, 2007 – Jan 18, 2011 · Past)
See Remarks · Mar 8, 2018 – Mar 29, 2019 · Past
Helen Susan Kim
Other companies: Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Prothena Corporation plc (Director · Aug 30, 2022 – May 14, 2025 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Aug 26, 2021 · Past); Exicure, Inc. (Director · Sep 26, 2017 – Jun 4, 2020 · Past); Kite Pharma Inc (EVP, Business Development · Apr 14, 2015 – Oct 3, 2017 · Past); Sunesis Pharmaceuticals Inc (Director · Jul 24, 2009 – Jun 30, 2015 · Past); Kosan Biosciences Inc (President and CEO · Jan 3, 2008 – Jun 26, 2008 · Past)
Director · Mar 8, 2018 – Jun 11, 2020 · Past
Gina Consylman
Other companies: Bluebird bio Inc (Chief Financial Officer · Nov 4, 2021 – Feb 1, 2022 · Past); Cyclerion Therapeutics, Inc. (SECRETARY AND TREASURER, Director · Mar 14, 2019 – Mar 14, 2019 · Past); Verastem, Inc. (Director · Oct 17, 2018 – Jun 28, 2021 · Past); Ironwood Pharmaceuticals, Inc. (SVP, CFO & Treasurer · Jun 23, 2014 – Mar 26, 2021 · Past); Analogic Corporation (VP-Controller · Mar 1, 2013 – Jun 11, 2014 · Past)
Director · Since at least Oct 19, 2020
Susan Mahony
Other companies: Axsome Therapeutics, Inc. (DIRECTOR · Since at least Oct 10, 2023); Zymeworks Inc. (Director · Since at least Jun 3, 2019); Eli Lilly and Company (SVP & Pres., Lilly Oncology · Jul 28, 2015 – Apr 13, 2018 · Past)
Director · Since at least Dec 14, 2017
Anthony Altig
Other companies: Optimer Pharmaceuticals Inc (Director · Jan 1, 2012 – Oct 24, 2013 · Past); TearLab Corporation (TEAR) (Director · Oct 1, 2011 – Jul 9, 2020 · Past)
Chairman of the Board, Non-Executive · Since at least Jan 17, 2012
John McHutchison
Other companies: Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Gilead Sciences, Inc. (Chief Scientific Off/HeadR&D · Apr 23, 2018 – Feb 6, 2019 · Past)
Director · Since at least Aug 6, 2019
Lee D Arnold
Other companies: Aethlon Medical, Inc. (Chief Scientific Officer · Feb 1, 2023 – Feb 1, 2023 · Past); Pardes Biosciences Inc (Chief Scientific Officer · Dec 23, 2021 – Feb 1, 2022 · Past)
Chief Scientific Officer · Jul 11, 2014 – Jul 11, 2014 · Past
Myron Holubiak
Other companies: Citius Oncology, Inc. (Secretary · Since at least Aug 12, 2024); Citius Pharmaceuticals, Inc. (Co-Founder, Executive Vice Chairman · Since at least Mar 28, 2018)
Director · May 30, 2018 – May 20, 2021 · Past
Sue Mahony
Other companies: Theravance Biopharma, Inc. (Lead Independent Director · Since at least Nov 4, 2026); Zymeworks Inc. (Lead Independent Director · Since at least Aug 11, 2025)
Director · Since at least Nov 4, 2026
All 37 people
PersonSeat
Alan Lewis
Other companies: BioMarin Pharmaceutical Inc. (Director · Jun 4, 2019 – Jun 4, 2019 · Past)
Director · May 17, 2019 – Jun 11, 2020 · Past
David Jonathan Barrett
Other companies: Fortress Biotech, Inc. (Director · Dec 19, 2013 – Feb 20, 2014 · Past)
See Remarks · Apr 5, 2013 – Mar 29, 2017 · Past
Derek A Small
Other companies: Innoviva, Inc. (Director · Since at least Apr 29, 2024)
Director · Jul 11, 2014 – Jan 2, 2020 · Past
Mark Auerbach
Other companies: Pardes Biosciences Inc (Director · Dec 23, 2021 – Aug 31, 2023 · Past)
Director · May 30, 2018 – May 17, 2019 · Past
Michael P Samar
Other companies: Unity Biotechnology Inc (Director · May 25, 2022 – Jun 21, 2024 · Past)
Chief Financial Officer · May 1, 2019 – Jul 25, 2022 · Past
Miguel Barbosa
Other companies: Synlogic Inc (Chief Scientific Officer · Sep 30, 2015 – Sep 30, 2015 · Past)
See Remarks · Oct 6, 2016 – Oct 6, 2016 · Past
Richard D DiMarchi
Other companies: Ionis Pharmaceuticals, Inc. (Director · Jul 3, 2006 – Jul 1, 2010 · Past)
Director · Jul 10, 2014 – May 25, 2022 · Past
Russell H Ellison
Other companies: Rockwell Medical, Inc. (See Remarks, Director · Jan 9, 2020 – May 3, 2021 · Past)
Chief Executive Officer, Director · Apr 5, 2013 – Jul 10, 2014 · Past
Thomas Joseph Russo
Other companies: Icosavax Inc (Chief Financial Officer · Jul 28, 2021 – Dec 20, 2023 · Past)
CFO · Oct 28, 2019 – Mar 29, 2021 · Past
Thomas Rowland
Other companies: ANI Pharmaceuticals, Inc. (Senior Vice President, Head of Established Brands · Since at least Mar 28, 2024)
Chief Business Officer · Dec 15, 2010 – Jan 15, 2012 · Past
Uri A Lopatin
Other companies: Pardes Biosciences Inc (Director · Dec 23, 2021 – Aug 31, 2023 · Past)
Chief Medical Officer · Jul 10, 2014 – Mar 29, 2019 · Past
Anuj GaggarChief Medical Officer · Since at least Nov 8, 2023
Jacqueline Sybil PapkoffSVP-CSO Microbiome · Apr 2, 2018 – Dec 14, 2020 · Past
Jason OkazakiChief Executive Officer & President, Director · Since at least Mar 26, 2020
Jeanette M BjorkquistPFO and PAO · Since at least Sep 9, 2022
Joseph FelderDirector · Dec 15, 2010 – Mar 6, 2013 · Past
Lisa Johnson-PrattDirector · Since at least May 20, 2021
Luisa M StammChief Medical Officer · Nov 6, 2019 – Mar 29, 2022 · Past
Michael HoughtonDirector · Since at least Jul 19, 2021
Nicole S WhiteChief Manufacturing Officer · Since at least Sep 13, 2023
Richard James ColonnoEVP & CSO, Virology Ops · Mar 29, 2017 – Mar 27, 2020 · Past
Rob CookDirector · Since at least Nov 4, 2026
Robert Donald Cook IIDirector · Mar 13, 2024 – Mar 13, 2024 · Past
Shannon RyanSVP, Investor Relations, Corporate Affairs and Alliance Management · Since at least Nov 7, 2025
Thomas E RollinsChief Development Officer · Feb 17, 2016 – Mar 29, 2018 · Past
Tomas CihlarDirector · Since at least Dec 7, 2023
William E Delaney IVChief Scientific Officer · Since at least May 27, 2020

Open People

Log in to ask 6ix AI your own questions about Assembly Biosciences, Inc.